Trofosfamide

CAS No. 22089-22-1

Trofosfamide( —— )

Catalog No. M26852 CAS No. 22089-22-1

Trofosfamide is a derivative of oxazaphosphorine with antineoplastic potency.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 34 In Stock
10MG 28 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Trofosfamide
  • Note
    Research use only, not for human use.
  • Brief Description
    Trofosfamide is a derivative of oxazaphosphorine with antineoplastic potency.
  • Description
    Trofosfamide is a derivative of oxazaphosphorine with antineoplastic potency.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    22089-22-1
  • Formula Weight
    323.58
  • Molecular Formula
    C9H18Cl3N2O2P
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (309.04 mM)
  • SMILES
    ClCCN(CCCl)P1(=O)OCCCN1CCCl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Oftedal L, et al. Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid. Sci Rep. 2020;10(1):22098. Published 2020 Dec 16.
molnova catalog
related products
  • Dynorphin A (1-11), ...

    Dynorphin A (1-11), porcine

  • 1H-1-ethyl Candesart...

    1H-1-ethyl Candesartan Cilexetil is a process-related impurity in the bulk synthesis of candesartan cilexetil, which is a potent, long-acting and selective angiotensin II type 1 receptor (AT1) antagonist.

  • [Tyr0] - Neurokinin ...

    Tyr0-Neurokinin A is a neuropeptide belongs to tachykinin peptide family. Tyr0-Neurokinin A is an agonist of Tacr2. Tyr0-Neurokinin A can be used in the research of insulin resistance, obesity, diabetes.